420 related articles for article (PubMed ID: 32430500)
1. Leukemia secondary to myeloproliferative neoplasms.
Dunbar AJ; Rampal RK; Levine R
Blood; 2020 Jul; 136(1):61-70. PubMed ID: 32430500
[TBL] [Abstract][Full Text] [Related]
2. Current clinical strategies and emergent treatment landscapes in leukemic transformation of Philadelphia-negative myeloproliferative neoplasms.
Abruzzese E; Niscola P
Expert Rev Hematol; 2020 Dec; 13(12):1349-1359. PubMed ID: 33226274
[No Abstract] [Full Text] [Related]
3. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
4. Secondary acute myeloid leukemias arising from Philadelphia chromosome negative myeloproliferative neoplasms: pathogenesis, risk factors, and therapeutic strategies.
Tallarico M; Odenike O
Curr Hematol Malig Rep; 2015 Jun; 10(2):112-7. PubMed ID: 25893311
[TBL] [Abstract][Full Text] [Related]
5. Relapse and cytogenetic evolution in myeloid neoplasms.
Ertz-Archambault N; Kelemen K
Panminerva Med; 2017 Dec; 59(4):308-319. PubMed ID: 29144072
[TBL] [Abstract][Full Text] [Related]
6. Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm.
Rampal R; Mascarenhas J
Curr Opin Hematol; 2014 Mar; 21(2):65-71. PubMed ID: 24366192
[TBL] [Abstract][Full Text] [Related]
7. Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work?
Kundranda MN; Tibes R; Mesa RA
Curr Hematol Malig Rep; 2012 Mar; 7(1):78-86. PubMed ID: 22170483
[TBL] [Abstract][Full Text] [Related]
8. A Concise Update on Risk Factors, Therapy, and Outcome of Leukemic Transformation of Myeloproliferative Neoplasms.
Mascarenhas J
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S124-9. PubMed ID: 27521308
[TBL] [Abstract][Full Text] [Related]
9. Blast Transformation in Myeloproliferative Neoplasms: Risk Factors, Biological Findings, and Targeted Therapeutic Options.
Iurlo A; Cattaneo D; Gianelli U
Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013941
[TBL] [Abstract][Full Text] [Related]
10. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
[TBL] [Abstract][Full Text] [Related]
11. [Precursors of acute leukemia: myelodysplastic syndromes and myeloproliferative neoplasms].
Kreipe HH
Pathologe; 2011 Nov; 32 Suppl 2():271-6. PubMed ID: 22033685
[TBL] [Abstract][Full Text] [Related]
12. Myeloid neoplasms with isolated isochromosome 17q represent a clinicopathologic entity associated with myelodysplastic/myeloproliferative features, a high risk of leukemic transformation, and wild-type TP53.
Kanagal-Shamanna R; Bueso-Ramos CE; Barkoh B; Lu G; Wang S; Garcia-Manero G; Vadhan-Raj S; Hoehn D; Medeiros LJ; Yin CC
Cancer; 2012 Jun; 118(11):2879-88. PubMed ID: 22038701
[TBL] [Abstract][Full Text] [Related]
13. Leukemic Transformation of Myeloproliferative Neoplasms: Therapeutic and Genomic Considerations.
Li B; Mascarenhas JO; Rampal RK
Curr Hematol Malig Rep; 2018 Dec; 13(6):588-595. PubMed ID: 30353413
[TBL] [Abstract][Full Text] [Related]
14. Can molecular insights guide treatment of AML evolved from MPNs?
Crispino J; Rampal R
Best Pract Res Clin Haematol; 2021 Dec; 34(4):101323. PubMed ID: 34865695
[TBL] [Abstract][Full Text] [Related]
15. MLL-PTD in a 13-year-old patient with blast phase myeloproliferative neoplasm: A case report.
He Z; Wang B; Chen L; Huang Y; Wang H; Yang M; Xiao X; Lu Y; Chen J; Wu Y
Medicine (Baltimore); 2018 Nov; 97(46):e13220. PubMed ID: 30431598
[TBL] [Abstract][Full Text] [Related]
16. Novel Molecular Insights into Leukemic Evolution of Myeloproliferative Neoplasms: A Single Cell Perspective.
Rontauroli S; Carretta C; Parenti S; Bertesi M; Manfredini R
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499582
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic options for leukemic transformation in patients with myeloproliferative neoplasms.
Khan M; Siddiqi R; Gangat N
Leuk Res; 2017 Dec; 63():78-84. PubMed ID: 29121538
[TBL] [Abstract][Full Text] [Related]
18. What are the molecular mechanisms driving the switch from MPNs to leukemia?
Wang X; Hoffman R
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101254. PubMed ID: 33762108
[TBL] [Abstract][Full Text] [Related]
19. Impact of gene mutations on treatment response and prognosis of acute myeloid leukemia secondary to myeloproliferative neoplasms.
Venton G; Courtier F; Charbonnier A; D'incan E; Saillard C; Mohty B; Mozziconacci MJ; Birnbaum D; Murati A; Vey N; Rey J
Am J Hematol; 2018 Mar; 93(3):330-338. PubMed ID: 29148089
[TBL] [Abstract][Full Text] [Related]
20. Acute myeloid leukemia following a myeloproliferative neoplasm: clinical characteristics, genetic features and effects of therapy.
Heaney ML; Soriano G
Curr Hematol Malig Rep; 2013 Jun; 8(2):116-22. PubMed ID: 23572311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
